Bladder cancer study testing a new drug combination before surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have muscle-invasive bladder cancer that has not spread beyond the bladder (stage cT2-T4aN0M0).
- Your tumor must have at least some HER2 protein (1+ or higher on a test).
- You are generally well enough to walk and take care of yourself (ECOG 0 or 1).
- You have not had certain prior treatments like immunotherapy or radiation for bladder cancer.
- Your kidney, liver, and blood function are within a healthy range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (Tislelizumab and Palbociclib) given before bladder removal surgery. It is for people with bladder cancer that has a specific genetic change and who cannot take the standard chemotherapy cisplatin.
This trial studies a combination of two drugs for bladder cancer that has not spread beyond the bladder. It aims to help patients who want to avoid bladder removal surgery, potentially preserving their bladder.
This study tests a combination of two drugs given directly into the bladder for a type of early-stage bladder cancer that has a specific protein marker called HER2. The goal is to see if the combination helps prevent the cancer from coming back.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.